The Blue Swan cover art

The Blue Swan

The Blue Swan

By: Sean Adler
Listen for free

About this listen

 In a landscape where innovation is a contact sport, The Blue Swan Podcast explores the science—and art—of thriving on the frontier. Hosted by Sean Adler—a visionary fitness leader, AI entrepreneur, and technical ninja with a sense of humor—whose journey spans the worlds of enterprise AI, bioinformatics, advanced calisthenics, and global media. His work and performances have been featured in Forbes, Fast Company, LA Fashion Week, and beyond. The Blue Swan is about more than just the pecking order. It’s about dancing on the razor’s edge of AI and entertainment, where quantitative rigor meets performance art, and the lines between data, movement, and storytelling are constantly redrawn. Through candid conversations with industry leaders, tech founders, athletes, and creative minds, The Blue Swan dives into what drives high-stakes performance—whether building agentic AI systems, pulling Hollywood stunts, optimizing risk, or biohacking. From regulatory navigation and portfolio optimization to martial arts, meditation, and the science of habit formation, you’ll hear stories and strategies you can use—no matter your arena. New episodes blend expert insight, creative exploration, and a dose of humor—because in business and life, adaptability is the ultimate edge. Sean's AI coaching apps are featured alongside Oscar, Grammy, and Tony award winners on Studio: https://studio.com/sean

seantzu.substack.comSean Adler Art Entertainment & Performing Arts
Episodes
  • Edwin Mata

    Edwin Mata
    Apr 30 2026
    Revolutionizing Asset Tokenization: Simplicity, Speed, and StructureEdwin Mata demystifies tokenization as the process of transforming real-world assets—such as real estate, equities, intellectual property, and luxury goods—into digital tokens that can be divided, distributed, and settled on a blockchain. Brickken’s platform streamlines the traditionally complex and bureaucratic world of securitization, enabling capital formation with unprecedented speed and efficiency. Crucially, Edwin emphasizes that tokenization is not a regulatory loophole; it is an efficiency layer that operates strictly within existing legal frameworks. “If something is not legal to be securitized or offered to the public, then it won’t be tokenized,” he asserts. Brickken’s technology accelerates compliant processes, offering features like T+0 settlement and one-click dividend distribution.The Power of Intangible Assets: IP, Royalties, and EntertainmentBrickken’s mission extends beyond tangible assets to the world of intangibles—intellectual property, royalties, music licensing, film rights, and event access. Edwin explains how tokenization empowers creators—musicians, filmmakers, and artists—to monetize their work and unlock new revenue streams, all while maintaining control and compliance. He highlights the challenges of navigating complex legal frameworks, such as sync licensing in music or FIFA’s strict IP rules for athletes. Brickken’s adaptable technology ensures that each asset’s unique legal structure is respected, empowering creators without overstepping regulatory boundaries.Bridging the Gap Between Technology and RegulationCompliance is at the heart of Brickken’s approach. Edwin details how the platform integrates Know Your Customer (KYC) protocols and accreditation checks to ensure offerings meet local securities laws. In the U.S., Brickken’s system enforces regulatory guardrails—blocking non-accredited investors and tailoring processes to frameworks like Regulation D. In Europe, the platform aligns with MiFID II and adapts to country-specific requirements. “We format the technology for you to be compliant under the regulation that you’re trying to enact,” Edwin explains, positioning Brickken as both an innovation engine and a compliance backbone.Tokenization Across All Asset Classes: From Diamond Rings to Biotech StartupsBrickken is redefining investor access to a diverse array of asset classes—from Picasso paintings and diamond rings to biotech startups and film productions. Tokenization democratizes access to previously illiquid markets, allowing investors to participate in short-term, high-yield opportunities once reserved for institutions. Edwin notes, however, that investor appetite often favors short-duration, high-liquidity, high-yield instruments—a reflection of Web3’s culture of instant liquidity. Successfully blending these expectations with the realities of real-world assets requires careful calibration and robust corporate governance, ensuring legal authority is established before tokenization proceeds.Valuation, Trust, and the Role of Certified PartnersTrust and transparency are central to Brickken’s model. The platform offers best-practice valuation guidance and connects issuers with certified valuation partners worldwide. These assessments can be embedded directly into smart contracts, creating a verifiable trust link between an asset’s value and what investors purchase. This is especially vital for early-stage or independent issuers who may lack established financial histories. While Brickken is not an auditor, its network of partners ensures credibility and rigor for every offering.The Derivatives Dilemma: Why Real-World Assets Are Not Digital-NativeEdwin addresses the complexities of creating derivatives for tokenized real-world assets. Unlike digital assets or commodities with real-time valuation and deep liquidity, real-world assets—like art or private equity—lack 24/7 valuation infrastructure. Attempting to create derivatives in such markets risks generating “fake markets” and destabilizing early participants. Edwin cautions against treating real-world assets as digital-native, emphasizing the need for robust market makers, liquidity providers, and real-time data before derivatives can safely flourish in this space.The Future of Tokenized Ecosystems: AI, Real-Time Valuation, and Mass DigitizationLooking forward, Edwin envisions artificial intelligence as a game-changer for real-time asset valuation. AI agents could continuously scan financial data and provide live valuation signals, unlocking the full potential of tokenized ecosystems. However, he warns that continuous information flow is a double-edged sword—real-time exposure could destabilize smaller companies not ready for public scrutiny. The goal is to balance transparency and efficiency with the stability needed for early-stage issuers to thrive.A Vision for the Future: The Great ...
    Show More Show Less
    27 mins
  • Eze Abosi

    Eze Abosi
    Apr 24 2026
    Visionary Leadership in Life SciencesEze Abosi is a trailblazer in the life sciences industry, leveraging over 20 years of expertise in healthcare, data analytics, and consulting to reshape how clinical and genomic data are utilized to improve patient care. As the Chief Growth Officer at Holmusk, a Series B-stage medical technology company backed by Novartis, Abosi leads sales, marketing, and service functions, driving the company’s mission to redefine neuropsychiatry and neuroscience research. Under his leadership, Holmusk has become a critical player in the integration of clinical and genomic data, empowering researchers, healthcare providers, and biopharma companies to address the most complex challenges in healthcare.Psychedelics: A New Dimension in Mental HealthAbosi and Holmusk are at the cutting edge of psychedelic drug development, a burgeoning field that promises to revolutionize the treatment of mental health disorders. As the U.S. FDA and other global regulators begin to fast-track the approval of psychedelic therapies, Holmusk plays a critical role by providing enriched datasets that help biotech companies like Compass Pathways and Atai Life Sciences advance their clinical trials.Abosi highlights the transformative potential of psychedelics, such as psilocybin and MDMA, in treating mental health conditions like depression and anxiety. With a focus on data enrichment, Holmusk supports these organizations by creating high-quality evidence to showcase the efficacy and safety of psychedelic therapies. “The lack of significant side effects in psychedelics, compared to traditional treatments like benzodiazepines, makes them a game-changer for patients,” Abosi explains. Holmusk is also helping to bridge the gap between hallucinogenic properties and therapeutic benefits by supporting research into second-generation psychedelics that isolate medicinal properties while minimizing hallucinogenic effects.AI Drug Development: Accelerating Discovery with DataArtificial intelligence in drug development is one of the most exciting and challenging frontiers in healthcare, and Abosi is positioning Holmusk at its forefront. By integrating high-quality, curated clinical data with cutting-edge machine learning techniques, Holmusk enables biopharma companies to de-risk the critical early stages of drug discovery and clinical research.Abosi explains that Holmusk’s datasets are particularly valuable for AI applications that aim to characterize patient populations and identify underserved subgroups. This capability is especially relevant in central nervous system (CNS) disorders, where Holmusk’s enriched datasets allow researchers to stratify patients by symptoms and develop therapies targeted at specific subpopulations, such as acute anxiety or treatment-resistant depression.Despite the potential of AI in drug development, Abosi notes that progress has been relatively slow, often stalling at Phase 2 trials. However, Holmusk is working to change that by fostering collaborations with researchers and biotech firms to accelerate the application of AI in clinical trials and commercialization. “AI is only as good as the data it’s applied to,” Abosi says. “Our role is to ensure that the data is robust, enriched, and capable of driving breakthroughs in drug development.”Pioneering the Intersection of Physical and Mental HealthOne of Holmusk’s most groundbreaking achievements lies in its ability to link physical and mental health outcomes through data. Abosi points to collaborations with institutions like Oxford University and Stanford’s Bioinformatics Department as examples of how Holmusk is breaking down silos in healthcare.A notable study conducted in partnership with Oxford explored correlations between GLP-1 medications (commonly used for cardiometabolic conditions) and mental health outcomes. Holmusk’s enriched datasets revealed meaningful insights into how these medications not only improve physical health but also impact cognitive function and mental health disorders like anxiety and depression. “This research represents the holy grail of healthcare,” Abosi says. “By looking at the patient holistically, we can establish critical links between physical and brain health.”The Skinny on GLP-1: Redefining Drug Market AccessBeyond research and development, Abosi is driving innovation in how drugs are commercialized and accessed. Holmusk collaborates with payers, pharma companies, and healthcare providers to create robust economic stories for new therapies. This is particularly critical in CNS disorders, where traditional approaches to drug development and commercialization often fall short.For example, Holmusk helps manufacturers demonstrate the economic value of their therapies by showing how premium-priced medications can reduce overall healthcare costs. Abosi provides the example of GLP-1 medications: although more expensive than generics like Metformin, GLP-1s have been shown to ...
    Show More Show Less
    29 mins
  • Aron D’Souza

    Aron D’Souza
    Apr 21 2026
    Aron D’Souza is not just a founder—he’s a visionary disruptor. From masterminding the revolutionary Hulk Hogan vs. Gawker lawsuit that redefined accountability in the media, to creating Objection AI, a groundbreaking truth arbitration platform, D’Souza’s career has been defined by audacity and relentless ambition. In this episode, he shares his journey of challenging societal norms and reshaping industries, offering a masterclass in leadership, innovation, and the art of building transformative ventures.The Gawker Lawsuit: A Blueprint for AccountabilityAron D’Souza’s rise to prominence began with a chance encounter at Oxford University in 2009, where he met Peter Thiel, the legendary venture capitalist and investor in Facebook, Spotify, and Palantir. What started as a casual conversation about media accountability turned into a five-year, $10 million legal crusade that culminated in a $140 million judgment for Hulk Hogan and the bankruptcy of Gawker Media. D’Souza reflects on the pivotal moment when he proposed his idea to Thiel: “I probably said the most important words of my life—‘If you don’t want to sue them, why don’t you find someone who wants to, but doesn’t have the financial resources to do so?’” The rest is history.The case, which remains one of the most consequential media lawsuits in American history, demonstrated the power of strategy, resilience, and focus. Now, D’Souza is taking the lessons from that legal battle and applying them to his latest venture, Objection AI, compressing the time and cost of holding media outlets accountable from years and millions of dollars to just weeks and a fraction of the price.Objection AI: The Court for the InternetWith Objection AI, D’Souza is tackling one of the most pressing issues of the digital age: the absence of a reliable truth arbitration system for the internet. This revolutionary platform allows individuals to challenge misinformation and media bias using a process inspired by both the judiciary and the scientific method. For as little as $2,000, Objection AI’s team of investigators—comprised of former CIA and FBI agents—analyzes media claims, compiles evidence, and creates a public data room for transparency. The journalist or media outlet in question is invited to respond, creating an adversarial process that mirrors a court of law.“Truth isn’t a vibe; truth is a process,” D’Souza asserts. He explains how the platform leverages both human expertise and AI to ensure rigorous truth-seeking. “The internet doesn’t have a native truth adjudication layer. Anyone can write anything, and it’s incredibly difficult to challenge false information. Objection AI changes that.”With a long-term vision of becoming “the court for everything,” Objection AI is poised to replace the judiciary’s slow-moving processes with an efficient, scalable alternative. “Even the wealthiest individuals can struggle to access justice in today’s legal system,” D’Souza notes. “We’re building a platform where truth is accessible to everyone.”The Enhanced Games: Superhuman Achievement RedefinedD’Souza’s ambition doesn’t stop at media accountability. As the president of the Enhanced Games, a $2.5 billion company poised to go public and challenge the Olympics, he’s redefining the limits of human potential. The Enhanced Games embraces performance-enhancing technologies under medical supervision, positioning itself as a bold alternative to traditional sports competitions. “The Olympics celebrates outdated ideals,” D’Souza says. “The Enhanced Games is about celebrating the future—pushing the boundaries of what humanity can achieve.”Guided by a scientific advisory board that includes luminaries like George Church, the world-renowned geneticist and co-founder of Colossal Biosciences, the Enhanced Games is breaking new ground in both sports and science. D’Souza credits Church’s involvement as pivotal, explaining how he cold-emailed the Harvard professor with his vision: “He didn’t even need the pitch. He just said, ‘I’m in. Let’s get to work.’” Together, they’ve developed groundbreaking protocols for enhancing athletes, turning the Enhanced Games into a global platform for superhuman innovation.Leadership Lessons from Rugby and StartupsD’Souza’s leadership style is deeply influenced by his time playing rugby at Oxford. “Rugby is simple—you have a unified goal: to win,” he says. This clarity of purpose has carried over into his ventures. Whether it’s the Enhanced Games or Objection AI, D’Souza emphasizes the importance of focus and mission-driven leadership. “Every great business feels a little bit dangerous,” he reflects. “Airbnb, Uber, OpenAI—they all started by challenging entrenched systems. The same is true for Objection AI and the Enhanced Games.”Having founded 12 startups with five successful exits, D’Souza has learned that talent is the ...
    Show More Show Less
    24 mins
No reviews yet